Immuneering Corporation  (IMRX)
Other Ticker:  
Price: $6.3900 $-0.07 -1.084%
Day's High: $6.5 Week Perf: -5.47 %
Day's Low: $ 6.20 30 Day Perf: 3.06 %
Volume (M): 37 52 Wk High: $ 14.29
Volume (M$): $ 236 52 Wk Avg: $8.09
Open: $6.49 52 Wk Low: $4.56

 Market Capitalization (Millions $) 187
 Shares Outstanding (Millions) 29
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -52
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Immuneering Corporation
Immuneering Corp is a biotechnology company that specializes in developing computational tools for drug discovery and precision medicine. It was founded in 2008 by Ben Zeskind and Harvard professor Mark Namchuk in Cambridge, Massachusetts.

The companyes main focus is to develop technology that can help identify new therapeutic targets and optimize drug development processes. The technology works by integrating vast amounts of data from various sources, including genomic, proteomic, and clinical data, to create a comprehensive understanding of disease biology.

Immuneering Corpes platform is built on proprietary algorithms and machine learning techniques that can analyze large and complex datasets. They use these tools to identify patterns and relationships that can help uncover the underlying mechanisms of disease and identify new drug targets.

The companyes technology is applicable across a wide range of therapeutic areas, including oncology, immunology, neurodegenerative diseases, and infectious diseases. Its clients include leading pharmaceutical and biotechnology companies as well as academic research institutions.

One of Immuneering Corpes unique offerings is their ability to identify mechanisms of drug resistance, which is a major challenge in drug development. They use their technology to analyze large patient datasets to identify why some patients do not respond to certain drugs, and use this information to identify new drug targets or optimize treatment regimens.

As of 2021, Immuneering Corp has raised over $117 million in funding from investors such as Omega Funds, Boxer Capital, and MiraeAsset. The company has also formed several strategic partnerships with leading pharmaceutical companies, including AbbVie and Sanofi.

   Company Address: 245 Main St Cambridge 2142 MA
   Company Phone Number: 500-8080   Stock Exchange / Ticker: NASDAQ IMRX
   IMRX is expected to report next financial results on March 05, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Immuneering's IMM-1-104 in Pancreatic Cancer Receives FDA Fast Track Designation, Accelerating Path to FDA Submission

Published Tue, Feb 20 2024 1:00 PM UTC

In a breakthrough development for Immuneering, the company has recently been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for their lead asset IMM-1-104 in the treatment of pancreatic ductal adenocarcinoma (PDAC). This exciting news has garnered considerable attention within the medical community as it holds the potential to expedite the drug...

Product Service News

FDA Green-Lights Immuneering's Milestone INV Application; Trailblazing Phase 1/2a Trial of IMM-6-415 on the Horizon

Published Tue, Dec 12 2023 1:01 PM UTC

Biopharmaceutical company Immuneering Corporation recently announced the United States Food and Drug Administration?s (FDA) clearance of their Investigational New Drug (IND) application. This landmark approval gives Immuneering the opportunity to move forward with their groundbreaking Phase 1/2a clinical trial of IMM-6-415 in patients suffering from advanced solid tumor...

Immuneering Corporation

Immuneering Corporation's Financial Results and Potential Impact on Future Operations and Revenue Growth

Immuneering Corporation, a renowned biotechnology company trading on the NASDAQ, has experienced a decline in stock value over the past five trading days. Despite this setback, the company's year-to-date performance remains commendable. Notably, Immuneering Corporation's financial results reveal noteworthy developments in their benchmarking efforts and revenue stability. As we explore these facts, it is essential to consider how they might impact the company's future operations and prospects.
1. Promising Benchmarking Results:
Immuneering Corporation recently conducted an expanded benchmarking study using its product, IMM-1-104, as a single agent across over 190 patient-aligned models in humanized 3D-tumor growth assays. These results demonstrated high sensitivity in various MAPK-driven tumor types, including RAS and RAF mutant melanoma, pancreatic cancer, and lung cancer. These findings indicate significant potential for IMM-1-104 to effectively combat a wide range of tumors. Should further studies confirm these results, Immuneering Corporation could benefit from increased demand for their product, potentially driving future revenue growth.

Immuneering Corporation

Immuneering Corporation Reports Promising Second Quarter 2023 Performance, Reveals Improved Profitability and Steady Financial Trajectory!

The recently released financial results for Immuneering Corporation's fiscal period ending June 30, 2023, have provided insights into the company's performance and direction. By examining various critical indicators such as per share loss, EPS improvement, revenue stability, and net shortfall, we can speculate on the possible impacts they may have on the company's future prospects.
Positive Shift in Per Share Loss and EPS:
In a positive development, Immuneering Corporation managed to decrease its per share loss from $-0.44 to $-0.43 compared to the previous year. Although seemingly small, this reduction indicates a gradual improvement in the company's ability to control its expenses. Furthermore, the EPS showcased an improvement from $-0.51 per share during the preceding reporting period, suggesting that Immuneering Corporation's profitability is heading in a positive direction. These indicators raise hopes for potential financial stability and increased confidence among stakeholders.

Immuneering Corporation

Headline: Immuneering Corporation's Diminishing Returns Intensify Further in January-March 2023

Investors in Immuneering Corporation may want to exercise caution, as the company continues to record disappointing financial figures. As of 12 months ending in the first quarter of 2023, Immuneering Corporation has recorded a cumulative net loss of $-51 million. This has resulted in a negative return on equity (ROE) of -44.24%, which is significantly lower than many other companies within the Major Pharmaceutical Preparations industry.
As of the current quarter, Immuneering Corporation ranks at 1417 in terms of overall ROE ranking. This is an improvement from the fourth quarter of 2022, where the company was ranked at 3326. However, we can see that there are still 49 other companies in the industry that have a higher return on equity. This presents a worrying picture of a company that is struggling to compete against its peers.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com